Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeyondSpring, a US-China Pharma, Files for $100 Million IPO

publication date: Nov 16, 2016
BeyondSpring Pharma, a virtual US-China company, filed to stage a $100 million IPO on the NASDAQ exchange. The company's business plan calls for integrating US and China clinical resources, making adept use of both to reduce cost and time. The company focuses on cancer-related therapies and plans to market them in the US and China. BeyondSpring will advance plinabulin as a treatment for neutropenia, and it is also testing the molecule, alone and as an adjunct to existing therapies, as a direct acting therapeutic for several forms of cancer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital